Chief Commercial Officer · AbCellera Biologics Inc. (ABCL)

Neil Aubuchon

FY2022 is the first fiscal year CompBrief holds for Neil Aubuchon as a named executive officer of AbCellera Biologics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2022

$5,566,290

Salary $400,000Stock awards $2,504,630Bonus $219,780

2nd of 5 named executive officers at AbCellera Biologics by FY2022 total.

5 named officers on file for AbCellera Biologics, FY2022

Neil Aubuchon’s pay file — $29

  • 1 fiscal year of pay, line by line
  • 4 equity grants, each cited to its filing
  • ABCL’s disclosed peer group of 20 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how AbCellera Biologics’s whole pay program stands against its peers

  • AbCellera Biologics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on ABCL→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 28, 2023 (DEF 14A).

Free

Get Neil Aubuchon’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Neil Aubuchon compensation by year

AbCellera Biologics Summary Compensation Table · the one fiscal year held
In US dollars, as AbCellera Biologics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2022
Salary$400,000
Bonus$219,780
Stock awards$2,504,630
Option awards$2,416,847
Pension and deferred compensation$0
All other$65,033
Total$5,566,290

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: AbCellera Biologics Inc. DEF 14A filed April 28, 2023, accession 0001140361-23-021664, and prior-year filings. Open the filing on EDGAR.

How this page was built: the AbCellera Biologics Inc. filed document, accession 0001140361-23-021664. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2023.

Equity holdings

unvested awards at FY2022 year-end
TypeUnvested unitsValue at year-endExercise price
RSU70,000$0—
RSU114,934$0—
Option173,451—$13.18
Option100,000—$14.14

Per the Outstanding Equity Awards at Fiscal Year-End table in AbCellera Biologics Inc.'s FY2022 proxy; value at the fiscal year-end close, as the company printed it.

Change-in-control & termination

estimated payments AbCellera Biologics discloses, by trigger · FY2022
TriggerCash severanceAccelerated equityBenefits continuationTotal as disclosed
Change in control and involuntary termination$560,000$1,873,381$1,943$2,435,324
Involuntary termination without cause$400,000$0$1,943$401,943

Per the Potential Payments Upon Termination or Change in Control table in AbCellera Biologics Inc.'s FY2022 proxy. Estimates as the company printed them; a dash means it printed no figure.

AbCellera Biologics’s named executive officers, FY2022

as the company reported each
Named executive officerRoleFY2022 total
Carl HansenChief Executive Officer$8,797,688
Neil Aubuchon · this pageChief Commercial Officer$5,566,290
Andrew BoothChief Financial Officer$4,887,681
Véronique LecaultChief Operating Officer$4,688,188
Tryn StimartChief Legal Officer, Chief Compliance Officer & Corporate Secretary$3,676,733

The full AbCellera Biologics compensation record

free company brief

This page is one person within AbCellera Biologics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are AbCellera Biologics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Neil Aubuchon's compensation dossier · One-time report. No refunds.